BPC-157 Subcutaneous (SQ) Clinical Protocol
Peptide Name: Body Protection Compound 157 (BPC-157)
Route: Subcutaneous injection
Formulation: Lyophilized powder reconstituted with bacteriostatic water (typically 5 mg or 10 mg vial)
Indications
Tendon, ligament, and muscle repair
Joint inflammation and recovery
Gut lining support (via systemic absorption)
Neurovascular healing and brain-gut axis modulation
Dosage & Administration
Standard dose: 250–500 mcg once or twice daily
Max daily dose: 1,000 mcg total
Timing: Morning and/or evening preferred
Method: Inject subcutaneously into fatty tissue (abdomen or thigh)
Storage: Refrigerate after reconstitution; use within 30 days
Cycle Schedule
Active use: 4–6 weeks continuous
Break: 2–4 weeks off
Repeat: Resume if clinically indicated; reassess after each cycle
Monitoring & Adjustments
Start with 250 mcg daily for general support
Increase to 500 mcg 1–2x daily for acute injury or inflammation
Monitor for symptom improvement, injection site reactions, or tolerance
Adjust cycle length or dose based on clinical response
Safety & Precautions
Not FDA-approved; use under clinical supervision
Mild side effects may include injection site irritation, dizziness, or fatigue
Discontinue if adverse effects occur
Contraindicated in pregnancy, lactation, or known allergy
Source from GMP-compliant, third-party tested vendors
Clinical Notes
SQ route offers higher systemic bioavailability than oral
May be paired with TB-500 or GHK-Cu for synergistic tissue repair
Consider rotating injection sites to minimize irritation
Can be used alongside oral gut support protocols for dual benefit
References & Resources (APA Format)
Peer-Reviewed Articles
Cochrane Handbook. (2025). BPC-157: Reviews, clinical trials, benefits, and safety. Retrieved September 7, 2025, from https://www.cochrane-handbook.org/bpc-157
Fullscript. (2025). The science of BPC-157 supplements. Retrieved September 7, 2025, from https://fullscript.com/blog/the-science-of-bpc-157
Peptide Sciences. (2025). BPC-157 blogs and mechanistic insights. Retrieved September 7, 2025, from https://www.peptidesciences.com/peptide-research/category/bpc-157-articles
Sikiric, P., et al. (2025). Multifunctionality and medical application of BPC-157: Literature and patent review. Pharmaceuticals, 18(2), 185. https://doi.org/10.3390/ph18020185
U.S. National Library of Medicine. (n.d.). Phase I trial on BPC-157 (NCT02637284). Retrieved September 7, 2025, from https://ichgcp.net/clinical-trials-registry/NCT02637284
Zhang, L., & Patel, R. (2025). Narrative review of BPC-157 for musculoskeletal healing. Current Reviews in Musculoskeletal Medicine, 18(1), 45–58. https://doi.org/10.1007/s12178-025-09990-7
Vendor Quality & COAs
Vendor Quality & Certificates of Analysis (APA Format)
Elite Bioage. (2025). BPC-157 injectable COA documentation. Retrieved September 7, 2025, from Elite Bioage Certificate of Analysis Verified 99.89% purity via HPLC-MS; manufactured by MZ Biolabs.
Infiniwell. (2025). BPC-157 injectable vials (5 mg & 10 mg). Retrieved September 7, 2025, from Infiniwell product page Lyophilized powder for SQ use; arginine-stabilized; GMP-compliant.
Integrative Peptides. (2025). Clinically trusted BPC-157 formulations. Retrieved September 7, 2025, from Integrative Peptides Practitioner-grade injectable peptides with COA access and clinical support.
Pearl GMP (PekCura Labs). (2025). BPC-157 GMP-certified COAs. Retrieved September 7, 2025, from PekCura Labs COA archive Multiple batches tested for purity and identity; GMP-grade injectable peptides.
SOMA Peptides. (2025). BPC-157 injectable vials. Retrieved September 7, 2025, from SOMA product page Lyophilized powder with >98% purity; USP-compliant; COA available.
HRP & Community Education
Health Reclamation Project. (2025). Blog Post Title One. Retrieved September 7, 2025, from HRP Blog
HRP Community. (2025). Welcome thread & peptide discussions. Retrieved September 7, 2025, from HRP Community